EIF4E and medulloblastoma: Importantly, in both medulloblastoma cell lines (Shh-subgroup and subgroup 3) the targeted inhibition of Mnk2 potently increased the antineoplastic action of rapamycin, likely by preventing activation of the Mnk2-eIF4E survival pathway.